- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -
TransMolecular, Inc. Presentation at ARVO 2009
Posted By Irv Arons On April 30, 2009 @ 5:52 pm In Industry News,Macular Degeneration,Meetings,New Technologies,Products,Research,Retina | Comments Disabled
TransMolecular, Inc. announced that new information on the anti-angiogenic method-of-action of TM601 will be presented at ARVO. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including ophthalmic disease and cancer.
Poster # 1164/D1126 is titled, “TM601, a Peptide That Binds Annexin A2, Causes Regression of Choroidal Neovascularization (CNV),”
TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease. Most recently, the effects of TM601 on the neovasculature have also been validated in animal models of ophthalmic disease, including wet age-related macular degeneration (AMD).
Read [1] the full release.
Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com
URL to article: http://eyedocnews.com/001019-transmolecular-inc-presentation-at-arvo-2009/
URLs in this post:
[1] Read: http://www.transmolecular.com/pdfs/ARVO_Media_Alert_FINAL_043009.pdf
Click here to print.
Copyright © 2008 Eye Doc Talk. All rights reserved.